“Driving home from your office, I could see my wife sitting next to me in the car, not just her hand on the steering wheel. There were cows by the side of the road. I could even see what color they were. My night vision improved, too.“ 57 year old man with retinitis pigmentosa.
Vision Protection Therapy™ (VPT™) improves the health and function of the retina in all chronic progressive retinopathies. This includes retinal diseases that are inherited.
“Now I can see the utensils in the kitchen drawer, and not have to feel around for them like I used to. I could see and recognize people’s faces at a party. I haven’t been able to do that for years. The other day, I ran late and was able to drive comfortably at dusk instead of calling someone to come get me.” 60 year old woman with Stargardt’s disease.
Retinitis pigmentosa results from one of more than 150 possible gene abnormalities that lead to gradual loss of peripheral vision, night vision, and eventually all vision. In Stargardt’s disease and Cone Degenerations, the inheritance and gene abnormalities are entirely different. In these, blindness is rare; but legal blindness (loss of central vision) is common.
“Everything is brighter and sharper. I can read better on my ipad.” 45 year old man with Usher’s syndrome.
Tests of retinal and visual function are generally abnormal in inherited retinal degenerations. Such abnormalities, and particularly worsening of retinal and visual function reflected in these tests, tends to predict future visual loss. VPT™ improves retinal and visual function in inherited retinal degenerations. By so doing, it is hoped that disease progression can be slowed, and the risks of vision loss reduced. This is the main goal of treatment. Over years, even a small reductions in the rate of disease progression can significantly reduce long-term the risks of visual loss. By restoring function to parts of the retina not previously working, VPT™ can actually reverse the disease process in many cases.
The goal of VPT™ in inherited retinopathies is improve retinal function and slow disease progression. Patients may or may not notice improvement in their vision, despite improvements in their retinal function and testing results. If you have visual acuity recordable on the eye chart, improvements of 1 to 3 lines if chart visual acuity are not uncommon following VPT™. For most patients, these improvements can be maintained for years with regular treatment. If your visual loss is substantial, VPT™ can still improve your visual function, but it will not restore normal vision or visual acuity.
Measurable improvements in retinal and vision function typically occur within hours of treatment. For patients noting visual improvement after VPT™ (approximately 2 out of 3 patients), these improvements are often noted within hours after treatment as well. Peripheral vision, night vision, and visual acuity can be improved, at times to levels not previously enjoyed for years. By 6 – 8 weeks after VPT™ many patients note the treatment improvements beginning to wear off. This is faster than other chronic progressive retinal diseases. This likely reflects the severity of retinal dysfunction in inherited retinopathies. Therefore, in inherited retinopathies, VPT™ needs to be repeated in order to maintain the treatment benefits and slow disease progression. By repeating VPT™ every 6-8 weeks, clinical experience indicates that the treatment benefits can be maintained for years.
“That night I could see stars again for the first time and 10 years. When I got home, I could walk through the house without all of the lights on.” 27 year old woman with retinitis pigmentosa.
Visual field tests of patient with Stargardt’s disease. Left side, before VPT. Right side, one month after SDM VPT. Note improvement in visual function by all testing indices.
How RP affects vision
How things look with Stargardt’s disease.